SPARC Share Price Jump Nearly 9%; Receives FDA Priority Review Voucher

Sun Pharma Advanced Research Company Ltd (SPARC) has received a Rare Pediatric Disease Priority Review Voucher (PRV) from the United States Food and Drug Administration (FDA) following approval of its drug Sezaby®. 

The incentive is aimed at encouraging pharmaceutical companies to develop treatments for rare pediatric diseases with limited therapeutic options.

SPARC Share Price Reacts Strongly

On February 3, 2026, as of 11:03 AM, SPARC share price was trading at ₹145.11, rising ₹11.61 or 8.70% compared to the previous close of ₹133.50. The stock opened higher at ₹143.00 and touched an intraday high of ₹148.30, while the day’s low stood at ₹137.60. 

What is a Priority Review Voucher?

A Priority Review Voucher allows a company to request an accelerated review for a future drug application, shortening the FDA review timeline significantly. The voucher is also tradable and can be sold to other pharmaceutical firms, making it a valuable strategic and financial asset.

Strategic Importance for SPARC

The PRV highlights SPARC’s continued focus on addressing unmet pediatric medical needs. The company plans to use the voucher to accelerate approvals within its pipeline, potentially bringing future therapies to market faster and strengthening its competitive position in specialty pharmaceuticals.

"Receiving this Priority Review Voucher is a significant milestone for SPARC and a testament to our commitment to addressing the urgent, unmet needs of patients," said Anil Raghavan, CEO of SPARC. "This award not only recognizes the therapeutic value of Sezaby® but also provides SPARC with additional strategic flexibility to accelerate our pipeline development to bring more therapies to patients faster."

Also Read: Sun Pharma Bets on Innovation as US Generics Pressure Eases, Speciality Drugs Drive Growth!

Conclusion 

The FDA’s grant of a Rare Pediatric Disease PRV marks a key achievement for SPARC, boosting investor confidence and enhancing pipeline prospects. With regulatory momentum and strong market response, SPARC strengthens its standing in the specialty drug development space.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.